m6A Regulator and Potential Drug Response

General Information of the m6A Regulator (ID: REG00030)
Regulator Name Insulin-like growth factor-binding protein 3 (IGFBP3)
Synonyms
IGFBP3; IBP3; IBP-3; IGF-binding protein 3; IGFBP-3
    Click to Show/Hide
Gene Name IGFBP3
Regulator Type WRITER ERASER READER
Regulator Link Click to View Full Information of This Regulator
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Insulin-like growth factor-I (IGF1)
Xentuzumab [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Insulin-like growth factor-I (IGF1) is a therapeutic target for Xentuzumab. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of Xentuzumab through regulating the expression of Insulin-like growth factor-I (IGF1). [1], [2]
BI-836845 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Insulin-like growth factor-I (IGF1) is a therapeutic target for BI-836845. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of BI-836845 through regulating the expression of Insulin-like growth factor-I (IGF1). [1], [3]
MEDI-573 [Phase 1]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Insulin-like growth factor-I (IGF1) is a therapeutic target for MEDI-573. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of MEDI-573 through regulating the expression of Insulin-like growth factor-I (IGF1). [1], [4]
Proto-oncogene c-Myc (MYC)
AVI-5126 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for AVI-5126. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of AVI-5126 through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [6]
Resten-NG [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [7]
TWS-119 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). [5], [8]
Thrombospondin-1 (THBS1)
ABT-510 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Thrombospondin-1 (THBS1) is a therapeutic target for ABT-510. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of ABT-510 through regulating the expression of Thrombospondin-1 (THBS1). [9], [10]
CVX-045 [Phase 2]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary Thrombospondin-1 (THBS1) is a therapeutic target for CVX-045. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of CVX-045 through regulating the expression of Thrombospondin-1 (THBS1). [9], [11]
VCAM-1 messenger RNA (VCAM1 mRNA)
ISIS 3792 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary VCAM-1 messenger RNA (VCAM1 mRNA) is a therapeutic target for ISIS 3792. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of ISIS 3792 through regulating the expression of VCAM-1 messenger RNA (VCAM1 mRNA). [12], [13]
ISIS 3801 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary VCAM-1 messenger RNA (VCAM1 mRNA) is a therapeutic target for ISIS 3801. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of ISIS 3801 through regulating the expression of VCAM-1 messenger RNA (VCAM1 mRNA). [12], [13]
ISIS 3804 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary VCAM-1 messenger RNA (VCAM1 mRNA) is a therapeutic target for ISIS 3804. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of ISIS 3804 through regulating the expression of VCAM-1 messenger RNA (VCAM1 mRNA). [12], [14]
ISIS 3805 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary VCAM-1 messenger RNA (VCAM1 mRNA) is a therapeutic target for ISIS 3805. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of ISIS 3805 through regulating the expression of VCAM-1 messenger RNA (VCAM1 mRNA). [12], [13]
ISIS 5874 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary VCAM-1 messenger RNA (VCAM1 mRNA) is a therapeutic target for ISIS 5874. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of ISIS 5874 through regulating the expression of VCAM-1 messenger RNA (VCAM1 mRNA). [12], [13]
ISIS 5875 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary VCAM-1 messenger RNA (VCAM1 mRNA) is a therapeutic target for ISIS 5875. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of ISIS 5875 through regulating the expression of VCAM-1 messenger RNA (VCAM1 mRNA). [12], [13]
ISIS 5876 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary VCAM-1 messenger RNA (VCAM1 mRNA) is a therapeutic target for ISIS 5876. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of ISIS 5876 through regulating the expression of VCAM-1 messenger RNA (VCAM1 mRNA). [12], [13]
ISIS 5884 [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary VCAM-1 messenger RNA (VCAM1 mRNA) is a therapeutic target for ISIS 5884. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of ISIS 5884 through regulating the expression of VCAM-1 messenger RNA (VCAM1 mRNA). [12], [13]
SYMBIOPOLYOL [Investigative]
In total 1 mechanisms lead to this potential drug response
 Drug Info 
Response Summary VCAM-1 messenger RNA (VCAM1 mRNA) is a therapeutic target for SYMBIOPOLYOL. The Insulin-like growth factor-binding protein 3 (IGFBP3) has potential in affecting the response of SYMBIOPOLYOL through regulating the expression of VCAM-1 messenger RNA (VCAM1 mRNA). [12], [15]
References
Ref 1 IGFBP3 Modulates Lung Tumorigenesis and Cell Growth through IGF1 Signaling. Mol Cancer Res. 2017 Jul;15(7):896-904. doi: 10.1158/1541-7786.MCR-16-0390. Epub 2017 Mar 22.
Ref 2 Terameprocol, a novel site-specific transcription inhibitor with anticancer activity. IDrugs. 2008 Mar;11(3):204-14.
Ref 3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 4 Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Mol Cancer Ther. 2014 Feb;13(2):399-409. doi: 10.1158/1535-7163.MCT-13-0598. Epub 2013 Dec 2.
Ref 5 The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells. Cancer Discov. 2021 Feb;11(2):480-499. doi: 10.1158/2159-8290.CD-20-0331. Epub 2020 Oct 6.
Ref 6 Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv. 2001 Oct;54(2):247-56. doi: 10.1002/ccd.1277.
Ref 7 Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154. doi: 10.1155/2011/483154. Epub 2010 Dec 27.
Ref 8 Anti-ageing pipeline starts to mature. Nat Rev Drug Discov. 2018 Sep;17(9):609-612. doi: 10.1038/nrd.2018.134. Epub 2018 Aug 3.
Ref 9 IGFBP3 inhibits angiogenesis through intracellular regulation of THBS1 expression. Am J Cancer Res. 2020 Jun 1;10(6):1728-1744. eCollection 2020.
Ref 10 Clinical pipeline report, company report or official report of Immune-Onc Therapeutics.
Ref 11 A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol. 2007 Jun;30(3):303-9. doi: 10.1097/01.coc.0000256104.80089.35.
Ref 12 IGFBP-3 stimulates human osteosarcoma cell migration by upregulating VCAM-1 expression. Life Sci. 2021 Jan 15;265:118758. doi: 10.1016/j.lfs.2020.118758. Epub 2020 Nov 12.
Ref 13 US patent application no. 5,843,738, Oligonucleotide modulation of cell adhesion.
Ref 14 Symbiopolyol, a VCAM-1 inhibitor from a symbiotic dinoflagellate of the jellyfish Mastigias papua. J Nat Prod. 2010 Jul 23;73(7):1318-22. doi: 10.1021/np100221k.
Ref 15 US patent application no. 6,312,900, Antisense oligonucleotide compositions and methods for the modulation of activating protein 1.